

Refine Search

Search Results -

Terms	Documents
L10 and (424/450).ccls.	88

Database:

US Pre-Grant Publication Full-Text Database
 US Patents Full-Text Database
 US OCR Full-Text Database
 EPO Abstracts Database
 JPO Abstracts Database
 Derwent World Patents Index
 IBM Technical Disclosure Bulletins

Search:

L11



Search History

DATE: Tuesday, October 09, 2007

[Purge Queries](#)
[Printable Copy](#)
[Create Case](#)

<u>Set Name</u> side by side	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u> result set
<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR</i>			
<u>L11</u>	L10 and 424/450.ccls.	88	<u>L11</u>
<u>L10</u>	lyso\$ adj10 liposome	332	<u>L10</u>
<u>L9</u>	lyso\$ adj15 liposome	395	<u>L9</u>
<u>L8</u>	L7 and 424/450.ccls.	84	<u>L8</u>
<u>L7</u>	lyso\$ same dppc	234	<u>L7</u>
<u>L6</u>	L5 and 424/450.ccls.	40	<u>L6</u>
<u>L5</u>	lyso\$ same dspc	140	<u>L5</u>
<u>L4</u>	lyso\$ adj10 dspc	2	<u>L4</u>
<u>L3</u>	mopc adj10 saturated	0	<u>L3</u>
<u>L2</u>	mopc adj10 dspc	0	<u>L2</u>
<u>L1</u>	mopc adj5 dspc	0	<u>L1</u>

END OF SEARCH HISTORY

[First Hit](#) [Fwd Refs](#)[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)

Generate Collection

Print

L6: Entry 35 of 40

File: USPT

Oct 13, 1998

DOCUMENT-IDENTIFIER: US 5820848 A

TITLE: Methods of preparing interdigitation-fusion liposomes and gels which encapsulate a bioactive agent

Detailed Description Paragraph Table (5):

TABLE 5 Lipid concentration 23.0 mM, 18.2 mg/ml Lyso PC content 0.9% Iotrolan entrapped 264.8 mg/ml Free Iotrolan 1.4% Iotrolan/DSPC 14.5 Captured Volume 13.7 .mu.l/.mu.mole Size distribution 90% less than 3.6 .mu.m 50% less than 2.8 .mu.m 10% less than 1.2 .mu.m

Current US Cross Reference Classification (3):

424/450

[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)

[First Hit](#) [Fwd Refs](#)[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)

End of Result Set



Generate Collection

Print

L6: Entry 40 of 40

File: USPT

Sep 1, 1992

DOCUMENT-IDENTIFIER: US 5143713 A

TITLE: .sup.99m Tc labeled liposomes

Detailed Description Text (12):

Liposome components are: distearoyl phosphatidylcholine (DSPC) (American Lecithin Company, Atlanta, Ga.), supplied as Phospholipid 100-H composed of 95% hydrogenated distearoyl phosphatidylcholine and up to 5% lysophosphatidylcholine; cholesterol (Calbiochem, San Diego, Calif.) at a purity of greater than 99% by TLC; and Dimyristoyl phosphatidyl DL-glycerol (DMPG) (Avanti Polar Lipids, Birmingham, Ala.) which was used without further purification. d-Alpha-tocopherol (Sigma, St. Louis, Miss.) was mixed in a 200 mg/ml solution in chloroform. All lipids were dried down from chloroform stock solutions in a mole ratio of 10:9:1 (DSPC:cholesterol:DMPG:alpha-tocopherol) and stored overnight in a vacuum desiccator to remove organic solvent. Samples were then rehydrated with solutions of trehalose (Pfanstiehl Laboratories, Waukegan, Ill.) in 30 mM phosphate buffered saline pH 7.4 and warmed in a water bath at 60.degree. C. for one hour.

Current US Cross Reference Classification (2):

424/450

[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)

[First Hit](#) [Fwd Refs](#)[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)

Generate Collection

Print

L8: Entry 65 of 84

File: USPT

Jul 11, 2000

DOCUMENT-IDENTIFIER: US 6086851 A

TITLE: Pharmaceutical compositions containing interdigitation-fusion liposomes and gels

Detailed Description Text (27):

mixed chain (saturated/unsaturated) lipids, such as SOPC and POPC, sterols and alpha-tocopherols which generally do not undergo interdigitation. Compounds added to IF gels after their formation can also include lipids which do undergo interdigitation-fusion. The compound can be an additional lipid such as transdielaidoyl phosphatidylcholine, dipalmitelaidoyl phosphatidylcholine, a lysolipid, for example, n-octadecyl-2-methylphosphatidylcholine, 1-laurylpropanediol-3-phosphocholine and erythro-N-lignoceroyl sphingophosphatidylcholine, a sphingolipid or a glycosphingolipid. It is generally preferred that when DOPC is employed, it be used with the saturated lipid DPPC, in no more than a proportion of 50 mole percent unsaturated lipid. One of ordinary skill in the art will recognize that the amount and type of additional lipid which may be included in compositions of the present invention may be varied within the teachings of the present application. Preferably, when the compound added to the IF gel is an additional lipid, this additional lipid has a transition temperature in the gel less than the transition temperature of the first lipid in the gel.

Current US Cross Reference Classification (4):

424/450

[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)

[First Hit](#) [Fwd Refs](#)[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)

Generate Collection

Print

L8: Entry 71 of 84

File: USPT

Oct 13, 1998

DOCUMENT-IDENTIFIER: US 5820848 A

TITLE: Methods of preparing interdigitation-fusion liposomes and gels which encapsulate a bioactive agent

Detailed Description Text (25):

In one embodiment of the invention, the method comprises adding additional material to the IF gel after its formation and prior to incubation to form IF liposomes. Aqueous-soluble compounds, such as bioactive agents, and lipid-soluble compounds, such as lipids and bioactive agents, can be added to the IF gel. Adding materials to IF gels after their formation is preferentially carried out for compounds which tend to interfere with interdigitation-fusion and which are not desirably part of the sized liposomes subject to interdigitation-fusion. Such compounds include non-interdigitating lipids, that is, lipids such as unsaturated lipids, mixed chain (saturated/unsaturated) lipids, such as SOPC and POPC, sterols and alpha-tocopherols which generally do not undergo interdigitation. Compounds added to IF gels after their formation can also include lipids which do undergo interdigitation-fusion. The compound can be an additional lipid such as transdielaidoyl phosphatidylcholine, dipalmitelaidoyl phosphatidylcholine, a lysolipid, for example, n-octadecyl-2-methylphosphatidylcholine, 1-laurylpropanediol-3-phosphocholine and erythro-N-lignoceroyl sphingophosphatidylcholine, a sphingolipid or a glycosphingolipid. It is generally preferred that when DOPC is employed, it be used with the saturated lipid DPPC, in no more than a proportion of 50 mole percent unsaturated lipid. One of ordinary skill in the art will recognize that the amount and type of additional lipid which may be included in compositions of the present invention may be varied within the teachings of the present application. Preferably, when the compound added to the IF gel is an additional lipid, this additional lipid has a transition temperature in the gel less than the transition temperature of the first lipid in the gel.

Current US Cross Reference Classification (3):

424/450

[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)

Refine Search

Search Results -

Terms	Documents
L7 and (424/450).ccls.	84

Database:

US Pre-Grant Publication Full-Text Database
 US Patents Full-Text Database
 US OCR Full-Text Database
 EPO Abstracts Database
 JPO Abstracts Database
 Derwent World Patents Index
 IBM Technical Disclosure Bulletins

Search:

L8



Refine Search

Recall Text



Clear

Interrupt

Search History

DATE: Tuesday, October 09, 2007

[Purge Queries](#)[Printable Copy](#)[Create Case](#)

<u>Set Name</u> side by side	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u> result set
<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR</i>			
<u>L8</u>	L7 and 424/450.ccls.	84	<u>L8</u>
<u>L7</u>	lyso\$ same dppc	234	<u>L7</u>
<u>L6</u>	L5 and 424/450.ccls.	40	<u>L6</u>
<u>L5</u>	lyso\$ same dspc	140	<u>L5</u>
<u>L4</u>	lyso\$ adj10 dspc	2	<u>L4</u>
<u>L3</u>	mopc adj10 saturated	0	<u>L3</u>
<u>L2</u>	mopc adj10 dspc	0	<u>L2</u>
<u>L1</u>	mopc adj5 dspc	0	<u>L1</u>

END OF SEARCH HISTORY

[First Hit](#) [Fwd Refs](#)[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)

Generate Collection

Print

L11: Entry 57 of 88

File: USPT

Jul 21, 1998

DOCUMENT-IDENTIFIER: US 5783566 A

**** See image for Certificate of Correction ****

TITLE: Method for increasing or decreasing transfection efficiency

Detailed Description Text (68):

Transfection efficiency can be increased by incorporating a lysophosphatide into the liposome formulation. The lysophosphatides can be present in amounts up to approximately a third of the total lipid concentration. Preferred lysophosphatides include lysophosphatidylcholines such as 1-oleoyllysophosphatidylcholine and lysophosphatidylethanolamines. Particularly preferred lysophosphatides are DOTMA, 1,2-bis(oleoyloxy)3-(trimethylammonio)propane (DOTAP), Lipofectin (GIBCO/BRL, Gaithersburg, Md.) and mixtures of these.

Current US Cross Reference Classification (1):424/450[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)